TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15236989

Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF) treatment during IUI
Number of subjects: 180
Study: 11958304

Group type: EXPERIMENTAL
Intervention: Hypothermic group (28 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tepid group (34 degrees C)
Number of subjects: 30
Study: 9717591

Group type: EXPERIMENTAL
Intervention: i.t. sufentanil plus 2.5 mg plain bupivacaine (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: i.t. sufentanil (Group A)
Number of subjects: 50
Study: 10641571

Group type: EXPERIMENTAL
Intervention: GM-CSF injected intradermally into a single dermal metastasis and into a normal skin site for 10 consecutive days at one of four dose levels (10, 20, 40, or 80 microg/injection)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Uninjected control tumors
Number of subjects: 16
Study: 1984617

Group type: EXPERIMENTAL
Intervention: TRACH MATE
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 142
Study: 6582073

Group type: EXPERIMENTAL
Intervention: Isotretinoin administered 1 hour before a meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotretinoin administered concomitantly with a meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotretinoin administered 1 hour after a meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotretinoin administered during a complete fast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotretinoin administered with food
Number of subjects: 20
Study: 30655277

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 µg
Number of subjects: 201

Group type: COMPARATOR
Intervention: tiotropium 5 µg
Number of subjects: 201

Group type: COMPARATOR
Intervention: tiotropium/olodaterol vs tiotropium
Number of subjects: 201
Study: 30046976

Group type: EXPERIMENTAL
Intervention: Supervised physical training intervention for 26 weeks post-RYGB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no supervised physical training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supervised physical training intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60
Study: 26913372

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study: 23210735

Group type: EXPERIMENTAL
Intervention: Peri-incisional triamcinolone acetonide (PITMC) injection
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no intralesional corticosteroids)
Number of subjects: 57
Study: 22307136

Group type: EXPERIMENTAL
Intervention: L1CAM downregulation via shRNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: L1CAM overexpression
Number of subjects: 0
Study: 19889502

Group type: EXPERIMENTAL
Intervention: MMD procedural preparation (MMD-PP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MMD distraction (MMD-D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard distraction (SD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hand held video game distraction (VG)
Number of subjects: 80
Study: 16876961

Group type: EXPERIMENTAL
Intervention: Self-regulation behaviors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy Alternatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy Alternatives, Self-regulation, Assertive Communication
Number of subjects: 0
Study: 16336546

Group type: EXPERIMENTAL
Intervention: Physician peer leader intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Peer leaders + asthma education nurses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 40
Study: 11886474

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg plus amoxicillin 1 g and clarithromycin 500 mg (Group A, n = 46)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Bismuth subcitrate 125 mg plus tetracycline 500 mg and furazolidone 200 mg (Group B, n = 46)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: No resistance to clarithromycin or amoxicillin
Number of subjects: 92
Study: 9032825

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 1689
Study: 8344690

Group type: EXPERIMENTAL
Intervention: n-IL-2 therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3755051

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brl 20627 (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study: 29306931

Group type: EXPERIMENTAL
Intervention: Exercise plus dieting (n=30)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dieting (n=20)
Number of subjects: 50
Study: 28030544

Group type: EXPERIMENTAL
Intervention: Soap and water
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sanitizer
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Calcium hypochlorite (HTH)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Generated or pH-stabilized sodium hypochlorite (NaOCl)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study: 24885187

Group type: EXPERIMENTAL
Intervention: trastuzumab-containing neoadjuvant therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: phospho-HER2 measurement
Number of subjects: 27
Study: 22325743

Group type: EXPERIMENTAL
Intervention: Communicative pain behaviors (eg, facial expressions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protective pain behaviors (eg, guarding)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pain behavior
Number of subjects: 0
Study: 20397977

Group type: EXPERIMENTAL
Intervention: Dependent one-lung ventilation (D-OLV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-dependent one-lung ventilation (ND-OLV)
Number of subjects: 40
Study: 18776819

Group type: EXPERIMENTAL
Intervention: Glycerol (oral)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Glycerol (oral) + Dexamethasone (intravenous)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dexamethasone (intravenous)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15930421

Group type: EXPERIMENTAL
Intervention: TAC (docetaxel plus doxorubicin and cyclophosphamide)
Number of subjects: 1491

Group type: COMPARATOR
Intervention: FAC (fluorouracil plus doxorubicin and cyclophosphamide)
Number of subjects: 1491
Study: 12906021

Group type: EXPERIMENTAL
Intervention: Oral Valganciclovir
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intravenous Ganciclovir
Number of subjects: 160
Study: 10589650

Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/kg) administered 2 min before vecuronium (0.1 mg/kg)
Number of subjects: 60
Study: 8886680

Group type: EXPERIMENTAL
Intervention: Hartmanns solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% Dextrose
Number of subjects: 0
Study: 1281726

Group type: EXPERIMENTAL
Intervention: Terazosin (10 mg/d)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 6374804

Group type: EXPERIMENTAL
Intervention: 750-ml collapsible spacer
Number of subjects: 18

Group type: COMPARATOR
Intervention: common actuator
Number of subjects: 18
Study: 30488466

Group type: EXPERIMENTAL
Intervention: Vasovagal syncope patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 76
Study: 30672174

Group type: EXPERIMENTAL
Intervention: Acupuncture A group (Tongdu Tiaoshen acupuncture, daily treatment)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acupuncture B group (Tongdu Tiaoshen acupuncture, treatment every other day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Medication group (nimodipine tablets, 30 mg three times daily)
Number of subjects: 180
Study: 27554943

Group type: EXPERIMENTAL
Intervention: Light-intensity walking interruptions every 20-min for one day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking interruptions every 20-min for one day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Light-intensity walking interruptions for three days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Uninterrupted sitting for one day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Uninterrupted sitting for three days
Number of subjects: 13
Study: 25029917

Group type: EXPERIMENTAL
Intervention: AP pressure applied to the cervical spine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (light touch applied to the right C6 costal process)
Number of subjects: 39
Study: 23237076

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 80
Study: 20219059

Group type: EXPERIMENTAL
Intervention: DDAVP (1-desamino-8-D-Arginine Vasopressin) for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 20
Study: 17038158

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Brisk walking (W)
Number of subjects: 121
Study: 16198847

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 522

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 522
Study: 12393368

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 micro g kg(‐1) h(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol 1 mg kg(‐1) h(‐1)
Number of subjects: 60
Study: 10457148

Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg daily for six weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study: 8778134

Group type: EXPERIMENTAL
Intervention: Single-cue anchoring manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequence anchoring manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consider-the-opposite procedure (cue sorting by diagnosticity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Note-taking while reviewing cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bias inoculation
Number of subjects: 0
Study: 2120769

Group type: EXPERIMENTAL
Intervention: 750 mg naproxen daily for a week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1000 mg naproxen daily for a week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Comparison of 750 mg and 1000 mg naproxen
Number of subjects: 80
Study: 911007

Group type: EXPERIMENTAL
Intervention: Daily drug reminder chart with concurrent pharmacist supervision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29861293

Group type: EXPERIMENTAL
Intervention: LaxVox
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VHFO
Number of subjects: 30
Study: 28784312

Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil (CF); two 3-weekly cycles of cisplatin [80 mg/m2 intravenously on day 1] and fluorouracil [1 g/m2 per day intravenously on days 1-4]
Number of subjects: 897

Group type: COMPARATOR
Intervention: Epirubicin, cisplatin, and capecitabine (ECX); four 3-weekly cycles of epirubicin [50 mg/m2], cisplatin [60 mg/m2], and capecitabine [1250 mg/m2 daily throughout the four cycles]
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil (CF)
Number of subjects: 897

Group type: COMPARATOR
Intervention: Epirubicin, cisplatin, and capecitabine (ECX)
Number of subjects: 897
Study: 25815774

Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy
Number of subjects: 268
Study: 23769759

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (EPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 20705516

Group type: EXPERIMENTAL
Intervention: Artesunate (100 mg) with sulfalene (250 mg) plus pyrimethamine (12.5 mg) for 3 days
Number of subjects: 212

Group type: COMPARATOR
Intervention: Praziquantel (40 mg/kg per day)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Artesunate with sulfalene plus pyrimethamine
Number of subjects: 212

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 212
Study: 18194560

Group type: EXPERIMENTAL
Intervention: Combined biomarker scoring system in the test set
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Test set
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 313
Study: 15842977

Group type: EXPERIMENTAL
Intervention: JTT-705 600 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 12895217

Group type: EXPERIMENTAL
Intervention: Dimethylpolysiloxane, sodium bicarbonate and pronase (treatment C)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Dimethylpolysiloxane alone (treatment A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Dimethylpolysiloxane plus sodium bicarbonate (treatment B)
Number of subjects: 87
Study: 10526276

Group type: EXPERIMENTAL
Intervention: Concurrent thoracic irradiation (50 grays in 20 fractions, initiated after the second cycle of chemotherapy)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Alternating thoracic irradiation (20 grays in 8 fractions followed by 15 grays in 6 fractions, scheduled between chemotherapy cycles)
Number of subjects: 164
Study: 8671452

Group type: EXPERIMENTAL
Intervention: Testicular spermatozoa (ICSI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ejaculated spermatozoa (ICSI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Total (Testicular + Ejaculated spermatozoa)
Number of subjects: 24
Study: 1750634

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6121577

Group type: EXPERIMENTAL
Intervention: Diacetolol 200 mg/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diacetolol 400 mg/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diacetolol 800 mg/day
Number of subjects: 17
Study: 30417724

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait (Lokomat, 60% robotic guidance)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Body weight-supported treadmill walking
Number of subjects: 14

Group type: COMPARATOR
Intervention: Body weight-supported overground walking
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait (Lokomat)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Body weight-supported treadmill and overground walking
Number of subjects: 14
Study: 28129680

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study: 25027257

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 149

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 149
Study: 22690324

Group type: EXPERIMENTAL
Intervention: Health literacy package
Number of subjects: 828
Study: 20653165

Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpu decoction
Number of subjects: 95

Group type: COMPARATOR
Intervention: Manyanshuning (Granula for Clearing the Throat)
Number of subjects: 95
Study: 19077889

Group type: EXPERIMENTAL
Intervention: Intraoperative surfactant treatment (bovine surfactant at a dose of 20 mg phospholipids/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intraoperative surfactant treatment
Number of subjects: 42
Study: 17187138

Group type: EXPERIMENTAL
Intervention: 1% ibopamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% ibopamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal individuals with either 1% or 2% ibopamine)
Number of subjects: 0
Study: 12810617

Group type: EXPERIMENTAL
Intervention: Transcutaneous ultrasound method for evaluating elasticity of atherosclerotic plaque
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous ultrasound method
Number of subjects: 0
Study: 10671820

Group type: EXPERIMENTAL
Intervention: Controlled, stimulated cycles (n = 33)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal menstrual cycles (n = 13)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 8892713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE), 0.625 mg/d
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE plus medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE plus MPA, 2.5 mg/d daily
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: CEE plus micronized progesterone (MP), 200 mg/d for 12 d/mo
Number of subjects: 875
Study: 1855298

Group type: EXPERIMENTAL
Intervention: Second-generation fructosamine assay
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: First-generation fructosamine assay
Number of subjects: 529
Study: 6681024

Group type: EXPERIMENTAL
Intervention: Minoxidil (5-40 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hydralazine (25-200 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 36
Study: 30623821

Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT-A)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Comorbid ADHD
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Comorbid DBDs
Number of subjects: 145
Study: 30149272

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 28269582

Group type: EXPERIMENTAL
Intervention: Progressive abduction loading therapy
Number of subjects: 31
Study: 25040338

Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison arms
Number of subjects: 84
Study: 22157929

Group type: EXPERIMENTAL
Intervention: Ketamine with midazolam premedication
Number of subjects: 201

Group type: COMPARATOR
Intervention: Ketamine without midazolam premedication
Number of subjects: 201
Study: 21042013

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate (increasing dose until serum total CO(2) ≥ 24 mM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (same medications, no sodium bicarbonate)
Number of subjects: 0
Study: 16697413

Group type: EXPERIMENTAL
Intervention: Sertraline with transdermal estrogen (ET)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sertraline with placebo
Number of subjects: 22
Study: 15908297

Group type: EXPERIMENTAL
Intervention: Thin petrolatum
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Thick petrolatum
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Thin 20% salicylic acid in petrolatum
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Thick 20% salicylic acid in petrolatum
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sunscreen
Number of subjects: 31
Study: 12910199

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 90
Study: 10235440

Group type: EXPERIMENTAL
Intervention: 5.1 g n-3 FA daily for 6 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 g n-3 FA daily for another 4 weeks (after initial treatment)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 23
Study: 8606810

Group type: EXPERIMENTAL
Intervention: PCR amplification using radioactive deoxynucleotides
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCR amplification using fluorescent oligonucleotide primers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of radioactive and fluorescent assays
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reporting and counselling procedures for presymptomatic testing
Number of subjects: 100
Study: 1720483

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study: 7022037

Group type: EXPERIMENTAL
Intervention: Cimetidine alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cimetidine and glucagon combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasogastric suction
Number of subjects: 20
Study: 31389157

Group type: EXPERIMENTAL
Intervention: 20 mg daily oral modified release morphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29494866

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Psychoeducational (PE)
Number of subjects: 30
Study: 26991683

Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'somewhat comfortable' discussing CAM
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'very comfortable' discussing CAM
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Nurses who self-reported use of massage
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Nurses with formal CAM education
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'somewhat comfortable' referring patients to CAM therapies
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Nurses who reported being 'very comfortable' referring patients to CAM therapies
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Nurses with formal CAM education referring patients to CAM therapies
Number of subjects: 699
Study: 24876156

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with EMG biofeedback and sham neuromuscular electrostimulation (NMES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with EMG biofeedback and intravaginal NMES
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with EMG biofeedback and transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 30
Study: 22844698

Group type: EXPERIMENTAL
Intervention: Low sodium diet (0.34 g/kg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Medium sodium diet (1.34 g/kg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High sodium diet (2.82 g/kg)
Number of subjects: 3